The Latest Advances in CAR T-Cell Therapy for Refractory and Relapsed Lymphomas and Leukemias
The goal of this activity is to provide healthcare professionals with the latest information regarding the use of CAR T-cell therapy in the management of relapsed and refractory lymphomas and leukemias.
This activity is intended for advanced practice registered nurses, nurses, hematologists-oncologists, and other healthcare professionals who treat and manage refractory and relapsed lymphomas and leukemias.
At the conclusion of this activity, participants should be better able to:
- Identify key features of the mechanism of action of CAR T-cell therapies in the setting of lymphomas and leukemias
- Devise management strategies that incorporate the efficacy and safety data for CAR T-cell therapies for relapsed or refractory lymphomas and leukemias
- Integrate CAR T-cell therapy into the overall treatment plan of a patient with relapsed or refractory lymphomas and leukemias based on current evidence
- Based on the current best evidence, implement strategies for managing toxicities associated with CAR T-cell therapy
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
Designated for 0.25 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
The faculty have reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: Marco L. Davila, MD, PhD, received income in any amount from: Kite Pharma, GBMG, Precision Bioscience, Servier; and ownership interest in Adaptive Biotechnologies. The medical writer, Larry Rosenberg, reports that neither he nor his spouse/life partner has any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.
The following planners and managers, Linda Gracie-King, MS; Jocelyn Timko; Claudine Kiffer; Larry Rosenberg; Annie Yueh; Pamela H. Viale, RN, MS, CNS, ANP; and Marilyn Haas, PhD, RN, CNS, ANP-BC, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Patricia Mangan, CRNP, has reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: advisory board for Kite Pharma; speakers bureau for Celgene, Takeda and Amgen. Stephanie Sutphin, PharmD, has reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: advisory board for Seattle Genetics and Amgen Biosimilars.
Method of Participation
Please visit Advanced Practitioner.com. Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, a statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within three weeks If you have questions regarding the receipt of your emailed certificate, please contact AXIS at firstname.lastname@example.org.
Safeguards Against Commercial Bias
AXIS Medical Education affirms that the content and format of the certified activity and its related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, AXIS employs several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for certified activities to ensure adherence to the Accreditation Council for Continuing Medical Education’s content validation guidelines, and resolution of any actual or perceived conflicts of interest that exist.
We employ several metrics during review of content materials, including: Fair balance (Recommendations must be based on a reasonable and valid interpretation of the information available on the subject matter; No single product or service is overrepresented when other equal, competing products or services are available for inclusion); and Scientific objectivity of studies mentioned in the activity or used as the basis for content development.
Disclosure of Unlabeled Use
This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Marco L. Davila, MD, PhD
Department of Blood and Marrow Transplantation
H. Lee Moffitt Cancer Center and Research Institute
Freelancer medical writer
This activity is provided by an educational grant from Kite Pharma, Inc.
There is no fee for this educational activity.
AXIS 1500 JADPRO 1
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Attendance